Regeneron to Add 2 New Bioreactors in NY Plant Expansion

Related tags Monoclonal antibodies Regeneron

Regeneron to Add 2 New Bioreactors in NY Plant Expansion
Regeneron will add two new 10,000-litre bioreactors at its East Greenbush facility as part of an $80m expansion.

The company is investing a total of $80m (€60m) on an expansion at the facility in New York, US, “to accommodate growth in [its] pipeline and commercial demand for [its] products,”​ Regeneron spokesperson Daniel Van Plew told our sister publication,

On top of the four 10,000-litre bioreactors currently at the site, an extra two will be added in a new 65,000 sq ft commercial-scale manufacturing site.

Though Van Plew said the growth could not be attributed “to any one product or to any particular regulatory approval,” ​the facility makes the firms lead product Eylea, a treatment for wet age-related macular degeneration.

According to Regeneron’s Q2 2013 results​, net sales of Eylea stood at $329.8m – up from $194m for the same period last year – comprising 72% of Regeneron’s total revenue for the quarter.

And Regeneron recently announced plans to boost monoclonal antibody production in Ireland with a deal that could see it buy a 400,000 sq ft facility in Limerick from computer manufacturer Dell. Read the full story here​.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers